News for Bellerophon Therapeutics, Inc. (BLPH)

NEW YORK, Dec. 26, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of SmileDirectClub, Inc....

U.S. stocks traded mostly higher this morning, with the Dow Jones gaining more than 200 points on Friday. Following the market opening Friday, the Dow traded up 0.74% to 33,880.85 while the NASDAQ rose 0.04% to 13,579.61. The S&P 500 also rose, gaining, 0.41% to 4,367.33.

Gainers Unique Fabricating, Inc. (NASDAQ: UFAB) shares surged 62.6% to $0.3512 in pre-market trading after gaining 12% on Thursday.

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.28% to 35,510.96 while the NASDAQ rose 0.91% to 14,187.05. The S&P 500, also rose, gaining, 0.48% to 4,576.60.

In the latest trading session, Bellerophon Therapeutics (BLPH) closed at $0.69, marking a -1.78% move from the previous day.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securiti...

Here is how Bellerophon Therapeutics (BLPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

U.S. stocks traded mixed toward the end of trading, with Dow Jones dropping over 100 points on Monday. The Dow traded down 0.33% to 33,651.23 while the NASDAQ rose 0.30% to 13,279.88. The S&P 500, also rose, gaining, 0.11% to 4,286.88.

During Monday's intraday session, major market indexes traded mixed as investors tried to assess the likelihood of the Fed hiking interest rates again next week.Looking at the...

Shares of Bellerophon Therapeutics Inc. plummeted 83% toward a record one-day decline, after the biotherapeutics company said its lung-disease treatment...

Bellerophon Therapeutics Phase 3 REBUILD Clinical Trial of INOpulse for Treatment of Fibrotic Interstitial Lung Disease Did Not Meet its Primary Endpoint

Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent...

But one pro says eye-popping numbers like these shouldn’t change the way you invest.

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.12%

Farmington, Jan. 16, 2023 (GLOBE NEWSWIRE) -- The Antihypertensive Drugs Market is estimated to reach a valuation of USD 30.2 Billion by 2022, growing at...

Read Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by Analysts at StockNews.com at ETF Daily News

Read Research Analysts’ Updated EPS Estimates for June 6th (BIDU, BLPH, BRSP, BURBY, BYRN, BZFD, CCCS, CHPT, CHRA, CNTA) at ETF Daily News

Read Analysts’ New Coverage for May 29th (AACG, AAME, ABEO, ACOR, ACRX, ACU, AEMD, AEY, AEZS, AGFS) at ETF Daily News